Impact Factor
3.59
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.48
764 total citations
h5-index
31
h5 depth signal
Cited share
78.4%
181 of 231
Total citations
764
Citation footprint
Metric signal
3.12
External metric anchor
Self-citation
2.4%
18 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
414
Italy
269
China
153
United Kingdom
88
Germany
75
Citing Fields of Research
Oncology
487
Immunology
217
Lung Cancer
163
Breast Cancer
161
Urology
139
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,699
Articles tracked across the journal lifetime
Indexed publication set
231
181 cited publications
Last 12 months
153
12.8 publications/month
Open access share
13.7%
21 OA publications in the last year
Leading citing country
United States
414 citing publications
Leading citing field
Oncology
487 citing publications
Latest tracked publication
15 October 2026
10 recent records available
Coverage & Indexing History
v1n1, June 2001-
v1n1, June 2001-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Breast Cancer
Lung Cancer
Immunology
Urology
Prostate Cancer
Broad Categories
Neoplasms
Therapeutics
Immunology
Urology
Liver & Colon Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1080/14737140.2026.2731196
Open DOI
How zongertinib was developed for HER2-mutant non-small cell lung cancer: a plain language summary
03
DOI 10.1080/14737140.2026.2746618
Open DOI
Targeting KIT and PDGFRA mutations in advanced GIST: current and future clinical implications
04
05
DOI 10.1080/14737140.2026.2738626
Open DOI
Real-world clinical and economic outcomes in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
1. Prostate cancer (PC) is the most common cancer in men. While most patients are diagnosed with localized disease, a subset of patients present with de novo metastatic disease [1]. Additionally, 1...
06
DOI 10.1080/14737140.2026.2738622
Open DOI
Targeting cancer stem cells with ribosome-inactivating proteins: from molecular mechanisms to clinical translation
1. Cancer is one of the toughest challenges in modern medicine because tumor cells have extremely complex and varied genetic changes[1]. In 2022, the International Agency for Research on Cancer (IA...
07
DOI 10.1080/14737140.2026.2738624
Open DOI
How does adding PD-(L)1 inhibitors to platinum-etoposide treatment of small cell lung cancer improve survival outcomes?
1. The introduction of immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis has improved survival outcomes in patients with both extensive stage (ES, 60–70% of cases) and limited stage...
08
DOI 10.1080/14737140.2026.2722166
Open DOI
Prospective patient preference study for chronic lymphocytic leukemia (CLL) treatment attributes impacting patient shared decision-making
1. Chronic lymphocytic leukemia (CLL) is a largely incurable and heterogeneous disease affecting approximately 220,000 individuals in the United States (US) [1,2]. Advances in the understanding of ...
09
DOI 10.1080/14737140.2026.2733840
Open DOI
Adjuvant therapy for resectable gastrointestinal stromal tumors: evidence, controversies, and practical guidance
10
DOI 10.1080/14737140.2026.2733834
Open DOI
Salivary duct carcinoma- contemporary nuts and bolts from pathologist perspective
1. Salivary gland carcinomas (SGC) are infrequent, heterogeneous tumors that represent less than 1% of all malignancies and 2–6% of all head and neck cancers [1–3]. SGC can be divided anatomically ...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.